Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728699 · ClinicalTrials.gov registry record
Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy
A clinical trial, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- 54
- Enrollment target
NCT03728699: Completed study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT03728699 is a clinical trial that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03728699 has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
This is a prospective, observational study to collect stool and blood from acute myeloid leukemia patients undergoing intensive chemotherapy.
Primary Outcome
Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform
Interventions
- DIAGNOSTIC_TEST Sample Collection Blood
- DIAGNOSTIC_TEST Stool Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2022-02-18 |
What the finished NCT03728699 record still lists
NCT03728699 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Sample Collection Blood is the first listed.
NCT03728699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03728699 about?
NCT03728699 is a clinical study titled "Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy". This is a prospective, observational study to collect stool and blood from acute myeloid leukemia patients undergoing intensive chemotherapy.
What is the current status of trial NCT03728699?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2018-01-02. Estimated completion is 2022-02-18.
What interventions are being tested in trial NCT03728699?
The interventions under investigation include: Sample Collection Blood (DIAGNOSTIC_TEST), Stool Sample (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03728699?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI